ArticleFrontiers in endocrinology2026
Inflammatory marker profiles vary by BMI across Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity represents a state of chronic low-grade inflammation, yet comprehensive comparative analyses examining systemic inflammatory markers across multiple immune-mediated inflammatory diseases (IMIDs) in relation to body mass index (BMI) categories remain limited. We evaluated how obesity-associated inflammatory burden manifests longitudinally across immunologically distinct conditions. Methods: We conducted a longitudinal cohort study using de-identified electronic health record data from the Optum Labs Data Warehouse, selecting adult patients with Crohn's disease (CD), ulcerative colitis (UC), psoriasis (PsO), or psoriatic arthritis (PsA) with at least two BMI measurements over five years. Using generalized mixed effects regression models, we estimated associations between BMI categories (healthy weight, <25 kg/m²; overweight, 25.0-29.9 kg/m²; obesity, ≥30 kg/m²) and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and ferritin. We compared patients with obesity and patients with overweight plus a high-risk comorbidity to the healthy-weight referent. Results: Across all four conditions, patients with obesity demonstrated significantly elevated CRP (49-83% higher) and ESR (24-48% higher) at baseline compared to healthy-weight counterparts. Patients with overweight plus high-risk comorbidities showed intermediate elevations (CRP 34-55% higher, ESR 13-30% higher). These patterns attenuated over time but remained statistically significant through year 5 in nearly all cohorts. Ferritin demonstrated near null associations across all conditions. Conclusion: Consistent CRP and ESR elevations across four immunologically distinct IMIDs, combined with null ferritin associations, suggest that excess adiposity may contribute to systemic inflammatory burden regardless of underlying disease mechanism, warranting further investigation of weight optimization as part of comprehensive IMID management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.